insights_auto
Why is ABVX down १७.२१%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
€ ६३.००
arrow_downward
-१७.२१%(-१३.१०) 1D
नोभेम्बर २०, १७:३८:५८ GMT+१ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€ ७४.५०
High
€ ७४.५०
Low
€ ५९.३०
Mkt. cap
५.५७ अरब
Avg. vol.
१.१३ लाख
Volume
८.४२ लाख
52-wk high
€ १३९.००
52-wk low
€ ५९.३०
EPS
-€ ५.२०
Shares outstanding
८.७५ करोड
No. of employees
९८
Open
€ ७४.५०
High
€ ७४.५०
Low
€ ५९.३०
Mkt. cap
५.५७ अरब
Avg. vol.
१.१३ लाख
Volume
८.४२ लाख
52-wk high
€ १३९.००
52-wk low
€ ५९.३०
EPS
-€ ५.२०
Shares outstanding
८.७५ करोड
No. of employees
९८
News stories
From web sources and news partners
Trefis
·
१ घण्टा पहिले
25 S&P 500 Stocks Just Made New 52-Week Lows
Chattanooga Times Free Press
·
१ घण्टा पहिले
S&P 500 sinks 3.7% and Nasdaq composite goes negative for the year as tech sell-off worsens
Traders Union
·
२ घण्टा पहिले
VIX fear index hits highest level since April 2025 as S&P 500 plunges
BigGo Finance
·
३ घण्टा पहिले
S&P 500 Falls for Seventh Straight Session, Enters Correction as AI Stock Rally Loses Steam
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees९८
Founded२०१३ डिसेम्बर ४
Headquarters-
SectorHealth Care
Industry-
Websiteabivax.com